Preview Mode Links will not work in preview mode

Sep 1, 2020

Proceedings from the second in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Ms Melony Avella-Howell, Dr Wells A Messersmith, Dr Philip A Philip and Ms Tammy Triglianos on the following topics:

  • Introduction (00:00)
  • Results of the Phase III IMbrave150 trial evaluating atezolizumab/bevacizumab for front-line unresectable hepatocellular carcinoma (HCC); benefits and risks in comparison to multikinase inhibitors (1:55)
  • Selection of first-line therapy for patients with advanced HCC; optimal timing of systemic treatment (14:06)
  • Efficacy and tolerability data from the Phase III IMbrave150 trial comparing atezolizumab/bevacizumab to sorafenib for front-line advanced HCC (22:48)
  • Significance of tumor location and biomarker profile in treatment decision-making for patients with metastatic colorectal cancer (mCRC); use of encorafenib/cetuximab for mCRC with BRAF mutation (37:16)
  • Safety and tolerability of regorafenib and TAS-102, each alone or in combination with bevacizumab, for patients with recurrent advanced CRC (47:00)
  • Optimal integration of immune checkpoint inhibitors into the therapeutic algorithm for patients with microsatellite instability (MSI)-high/mismatch repair (MMR)-deficient mCRC; emerging data with pembrolizumab versus chemotherapy in the up-front setting (53:45)
  • Management of side effects from TAS-102; optimal sequencing of TAS-102 and regorafenib for recurrent mCRC (1:00:19)
  • PD-L1 expression and immune checkpoint inhibitor therapy for metastatic gastroesophageal cancer (1:08:57)
  • FDA approval of TAS-102 for patients with heavily pretreated metastatic gastric cancer; appropriate use in clinical care (1:14:18)
  • Impact of COVID-19 on the clinical care of patients with gastrointestinal cancers (1:18:41)

CNE information and select publications